Clinical evaluation of cefmetazole for the prevention of postoperative wound infections

The authors treated 415 patients, with injection of 4 g cefmetazole (CMZ) per day after operation of the digestive tract. In these cases, the prevention of postoperative wound infections was investigated and the following results were obtained. Out of 415 cases, 11 cases (2.7%) had postoperative wound infections; 6 cases of which were superficial wound infections and 5 cases deep wound infections. In relation to the degree of infection of the surgical field of them, 10 cases were performed with the contamination by bowel organisms and 1 case was in infected surgical field. Bacteriological examination was carried out. Twenty-four strains of bacteria were isolated and identified. The major bacterial strains identified were 6 strains of S. faecalis, 4 strains of E. cloacae and 4 strains of P. aeruginosa. These organisms were rarely sensitive to CMZ. The results suggest that the organisms causing postoperative wound infections are changing compared with the organisms of previous reports and that the use of CMZ as a postoperative medication is useful in the prevention of wound infections.     

Prophylactic effect of fosfomycin on postoperative infection in gastroenterological surgery

Fosfomycin (FOM), a drug with unique mechanism of action against bacteria, was prospectively compared with cefmetazole (CMZ) and flomoxef (FMOX) to assess its effectiveness in preventing postoperative infections after upper gastroenterological and hepatobiliary surgery. FOM (2g/dose), CMZ (1 g/dose), or FMOX (lg/dose) was infused intravenously 2-3 times daily for basically 4 days including the day of surgery in order to examine whether or not infections would develop after surgery. According to the analysis results of 162 cases, efficacy in preventing infection was 86.8% for FOM, 73.1% for CMZ and 83.3% for FMOX, showing no significant differences among the 3 groups. Thus FOM was considered as efficacious as CMZ or FMOX in prophylaxis against postoperative infections. There were no adverse reactions in the FOM or CMZ group, but 3 cases of adverse reactions occurred in the FMOX group. Based on the above results, the usefulness of FOM for prophylaxis against postoperative infections has been confirmed. At present, the first- and second-generation cephems are most frequently used for prophylaxis against postoperative infections. In order to prevent an increase of resistant strains due to inappropriate use of these drugs, FOM, having no cross resistance with currently used drugs, is a promising candidate for prophylaxis against postoperative infections.     

Laboratory and clinical studies of flomoxef

Laboratory and clinical studies were performed on a new oxacephem antibiotic, flomoxef (FMOX, 6315-S). In vitro antibacterial activity of FMOX was evaluated in comparison to latamoxef (LMOX), cefmetazole (CMZ), cefazolin (CEZ) using clinically isolated strains of Gram-negative and Gram-positive bacteria. Antibacterial activities of FMOX were stronger than LMOX, CMZ, CEZ against Escherichia coli, Klebsiella but only slightly effective against Staphylococcus aureus. This antibiotic drug was administered to 5 patients consisting of 2 cases with pneumonia, one each with pyelonephritis, chronic bronchitis and urinary tract infection. The drug was given in 1 g drip infusion twice a day for 8 to 13 days. Clinical efficacies of FMOX were excellent in 1 case, good in 2, fair in 1, and unevaluable in 1. As for bacteriological effect of FMOX, organisms were eradicated in 3 cases. No side effect was noted and there was no abnormal change in laboratory findings.     

Basic and clinical evaluations of cefmetazole in postoperative wound infections

The time course of the concentration of cefmetazole (CMZ) in the serum and in skin and intestinal tissues was determined after a single intravenous injection of 2 g of the drug. CMZ moved into them well. Furthermore, 41 patients with postoperative wound infection (superficial in 29 and deep in 12) were treated with CMZ 2-4 g daily. Bacteriological examination of the lesions with simultaneously carried out. As a result, 101 strains of bacteria were isolated and identified. Mixed infection was found in 27 cases (65.9%). Fifteen strains (14.9%) of E. coli, 15 (14.9%) of B. fragilis, 7 (6.9%) of Klebsiella sp. and 7 (6.9%) of Proteus sp., were the main bacteria isolated. Eight cases (19.5%) had mixed infection of E. coli and B. fragilis. The committee (3 members) evaluated CMZ to be effective in 75.6% (31 of 41 cases) and bacteria disappeared in 60.5% (23 of 38 cases). The side effects observed were pyrosis and feeling of gastric malaise in 1 case. The results suggest that CMZ is useful, which exerts an excellent effect on postoperative wound infections.     

Basic and clinical studies on the effect of cefmetazole on infection in gyneco-obstetrics

Cefmetazole (CMZ) was administered to 102 infectious cases in the gynecoobstetric patients, and the basic and clinical studies have been performed. The main findings obtained in the present study are: Amont 78 cases of CMZ administration immediately after the initial infection (A group), 42 remarkably effective (53.8%), 36 effective (46.2%) cass were observed. When other drugs were not effective after the initial infection, CMZ was administered (B group) to 24 cases, and 15 remarkably effective (62.5%), 9 effective (37.5%) cases were observed. overall effectiveness in the A and B groups was 57 remarkably effective (55.9%) and 45 effective (44.1%) cases, which are very excellent clinical effects. Among 102 cases, the pathogenic bacteria were found in 55 cases, and 29 cases out of the 55 (52.7%) showed infections with E. coli and with other bacteria having mixed infections. The effect of CMZ to E. coli as judged by MIC was excellent, providing the excellent clinical results. E. coli and other Gram-negative pathogenic bacteria in the B group showed resistance to ABPC, CEX, CEZ and CET, and after administering CMZ, all cases showed disappearance of these bacteria, but the increase in the resistant bacteria for CEX, CET and CEZ was obviously shown. Subjective and objective adverse effects and clinical laboratory analysis showed no abnormal effect and values due to CMZ, and it was true of the of the case received 140 g in total of CMZ over 35 days, 4 g/day. It may be conducted from the above findings that CMZ is very effective and safe antibiotic agent in the infections in the gynecoobsterics .     

Therapeutic effects of a combination treatment with cefmetazole and netilmicin against infections complicated with hematological disorders

The efficacy and safety of a combination regimen using cefmetazole (CMZ) and netilmicin (NTL) were evaluated in the treatment of infections complicated with hematological disorders. Primary diseases in 31 patients included in the evaluation were acute myelocytic leukemia (3 cases), acute lymphocytic leukemia (2 cases), malignant lymphoma (14 cases), chronic myelocytic leukemia (2 cases), chronic myelocytic leukemia blast crisis (4 cases), myelodysplastic syndrome (2 cases), aplastic anemia (3 cases), and malignant histiocytosis (1 case). Complicated infections included 29 cases of suspected septicemia, 1 case of septicemia and 1 case of pneumonia. Clinical responses were excellent in 6 (19.4%), good in 12 (38.7%), fair in 1 (3.2%) and poor in 12 (38.7%). The total clinical efficacy rate was 58.1%. No significant effect of initial neutrophil counts was observed on response rates. Patients who showed increasing neutrophil counts during therapy had higher response rates than those in whom the neutrophil count decreased or remained unchanged at levels less than 500/mm3 in after neutrophil counts. No side effects were observed in any of the 31 patients. In conclusion, this combination therapy of CMZ and NTL thus appears to be useful and safe in therapies for infections complicated with hematological disorders.     

Clinical study of S 6472 in urinary tract infection

Clinical studies on S 6472, a longer lasting preparation of cefaclor (CCL), were performed and the following results were obtained. S 6472 was administered orally to 102 patients with urinary tract infections including 16 with acute uncomplicated pyelonephritis, 32 with acute uncomplicated cystitis, 31 with complicated pyelonephritis and 23 with complicated cystitis. 95 patients were treated with 375 mg of S 6472 2 times daily and 7 patients were treated with 750 mg of S 6472 2 times daily. The overall clinical efficacy was evaluated on the basis of the criteria proposed by the Japanese UTI Committee. 1. Clinical efficacies in 11 cases of acute uncomplicated pyelonephritis were excellent in 10 and moderate in 1, with an overall efficacy rate of 100%. Bacteriologically, all 12 strains identified in the acute uncomplicated pyelonephritis cases were eradicated, with an eradication rate of 100%. 2. Clinical efficacies in 21 cases of acute uncomplicated cystitis were excellent in 17, moderate in 3 and poor in 1, with an overall efficacy rate of 95%. As to bacteriological responses, 22 strains identified in the acute uncomplicated cystitis cases (except 1 of Escherichia coli) were eradicated, with an eradication rate of 95%. 3. Clinical responses in 43 cases of complicated urinary tract infections were excellent in 20, moderate in 15 and poor in 8, with an overall efficacy rate of 81%. Bacteriologically, 39 strains, including only one strain of P. aeruginosa, in the complicated urinary tract infection cases (except 4 of E. coli, 1 of Klebsiella pneumoniae, 1 of Enterococcus faecalis and 2 of Enterobacter cloacae) were eradicated, with an eradication rate of 83%. As side effects, slight stomatitis and gastric discomfort were noted in 1 patient each but we were able to continue the medication. Abnormal laboratory test values found were: 1 case of a slight and transient increase of lymphocytes in peripheral blood and 1 case of a slight and transient increase of serum creatinine level.     

Successful combination therapy of teicoplanin with cefmetazole on postoperative cardiovascular MRSA infections: clinical report on two cases

We clinically evaluated the efficacy of the combination therapy of teicoplanin (TEIC) with cefmetazole (CMZ) in two patients, one (case 1) had developed surgical site infection and the other (case 2) mediastinitis caused by methicillin-resistant Staphylococcus aureus (MRSA) after cardiovascular surgeries. TEIC (400 mg twice a day on day-1 and 400 mg once a day thereafter) was administered intravenously immediately after the end of drip infusion of CMZ (1.0 g twice a day). Both patients showed marked improvement on the 5th-day. The isolated MRSA from these two cases were subjected to the in vitro studies and synergistic effects between TEIC and CMZ were recognized under the checkerboard method. Thus, the favorable effects of the combination therapy might be attributable to the synergy between TEIC and CMZ recognized in vitro. These results suggest that the combination therapy of TEIC with CMZ may be useful in the treatment of severe MRSA infections.     

Clinical study of cefmenoxime in the field of abdominal surgery

The effect of cefmenoxime (CMX) was evaluated in the abdominal surgery at 18 hospitals on the prevention and the treatment of postoperative infections. The results were summarized as follows. In 179 patients with prophylactic use of 2-4 g of CMX a day, no postoperative infection was observed in 94.4%. Using fever index to judge the effect of CMX in prevention of postoperative infections, the value of fever index was higher in the infected group than in the non-infected group. A significant difference was also observed in mean fever index value between the groups given CMX in 2 g and 4 g daily, being 15.4 degree hours and 1.7 degree hours. The incidence of postoperative infections was higher in cases with intraoperative bleeding of more than 500 ml than in cases with less bleeding. Postoperative infection and peritonitis subsided after the administration of 2-4 g of CMX/day for more than 8 days in 77.1% of cases. Very few side effects were noted due to CMX. These results suggest that CMX is safe and effective in the field of abdominal surgery for the prevention of postoperative infections and in the treatment of postoperative infections.     

Pharmacokinetics and clinical studies of cefmetazole in the otorhinolaryngological field

Cefmetazole (CMZ), a new cephamycin preparation, has been investigated to give following results. 1) Pharmacokinetics: Serum and tonsil concentration of CMZ were determined by micropore method in humans. The mean concentrations in 5 cases about 30 minutes after administration of 0.5--1.0 g intravenously were 55.4 micrograms/ml in serum, 21.7 micrograms/g in tonsil. 2) Clinical studies: Seventy-one patients with ear, nose and throat infections were treated with CMZ receiving 1 to 6 g per day intravenously (one shot and drip infusion). Thirty-eight of 70 patients were cured excellent, 19 were good, 8 were fair and 6 were failure and effective rate was 80.3%. Adverse reaction was observed in 4 cases. Three cases showed exanthema and 1 case showed fever elevation.     

Clinical study on effects of cefmetazole on severe infections accompanied by hematologic diseases

Severe infections accompanied by hematopathy under granulocytopenic conditions were treated with cefmetazole (CMZ). Subject diseases mainly consisted of acute leukemia, agranulocytosis and aplastic anemia; combined infections were septicemia, pneumonia, fever of an undetermined origin, etc. As for causative organisms found in cases that could be examined, Gram-negative bacilli such as Klebsiella pneumoniae, Klebsiella oxytoca, Pseudomonas aeruginosa and Enterobacter cloacae were isolated, as was Staphylococcus aureus. In general, 4 g of CMZ divided into 2 administrations was given per day through intravenous injection or intravenous drip infusion. On the basis of the judgement criteria for effectiveness established by Takaku et al., the efficacy rate in this study was found to be 68%, including 2 cases that showed excellent responses to treatment of infections caused by S. aureus. Cases that showed pyretolysis within 4 days had over 1,000/microliter of neutrophils, while cases with less than 1,000/microliter showed no pyretolysis. No hepatorenal dysfunctions related to the treatment with CMZ were seen as side effects except increases of transaminase in 1 case. These results indicate that CMZ is a useful drug for the treatment of infections accompanied by hematopathy under granulocytopenic condition.     

比阿培南在经皮肾镜取石术中的应用

目的 评价比阿培南在经皮肾镜取石术(PCNL)中防治感染的疗效.方法 收集68例PCNL并使用比阿培南防治感染患者的临床资料,评价比阿培南在PCNL中防治感染的治疗效果.结果 57例PC-NL围术期使用注射用比阿培南每次0.3g,每天2次静脉滴注7～14d,能有效防治术后感染;11例PCNL后出现泌尿系感染并全身炎性反应综合征,改用注射用比阿培南每次0.3g,每8小时1次静脉滴注7～14d,均能够有效治疗术后感染.结论 比阿培南在PCNL中防治感染的疗效确切.     

Pharmacokinetic, bacteriological and clinical evaluation of sulbactam/ampicillin in pediatrics

The pharmacokinetics, efficacy and safety of sulbactam/ampicillin (SBT/ABPC) were evaluated in 21 children with a variety of infections. The results obtained are summarized as follows. 1. Pharmacokinetics in 4 children, each receiving a single dose of 60 mg/kg, were evaluated. The average half-life of SBT was 1.03 hours and that of ABPC was 0.83 hour. 2. In vitro antimicrobiol activity (MIC) of SBT/ABPC in which SBT and ABPC are combined at a ratio of 1:2 was stronger than ABPC alone and was quite effective against Staphylococcus aureus and Haemophilus influenzae, but activity against Escherichia coli was relatively low. Antimicrobial activity of SBT/ABPC against S. aureus was almost equal to those of piperacillin (PIPC), cefazolin (CEZ) and cefmetazole (CMZ), but against H. influenzae was stronger than those of CEZ and CMZ. Activity against E. coli was lower than those of PIPC, CEZ and CMZ. 3. A total of 21 patients including 3 with pharyngitis, 10 with bronchitis, 5 with pneumonia, 1 each with acute enteritis, pyelonephritis and suspected sepsis were treated with SBT/ABPC. The clinical efficacy rate for these patients was 95.2% (20/21). The bacteriological eradication rate was 80% (8/10). 4. There were 4 instances of side effects, 1 case each of eruption, diarrhea, thrombocytosis and eosinophilia, but all symptoms were transient.     

Clinical evaluation of amoxicillin sustained-release preparation in urinary tract infection

C-AMOX, a new prolonged acting preparation of amoxicillin was administered to 122 cases by oral administration of daily dosage 500 mg twice. Clinical effectiveness of C-AMOX was evaluated in 115 out of 122 cases (acute simple cystitis 87 cases, acute pyelonephritis 6 cases, complicated urinary tract infection 19 cases and others 3 cases), and the following results were obtained. 1. The clinical effect for 87 cases of acute simple cystitis was excellent in 54 cases (62%), moderate in 24 cases (27.6%) and poor 9 cases (10.3%), overall effective rate being 89.7%. 2. The clinical effect for 19 cases of complicated urinary tract infection was excellent in 6 cases (31.6%), good 8 cases (42.1%) and poor 5 cases (26.3%), overall effective rate being 73.7%. 3. Adverse reaction occurred in 2 patients, one gastric discomfort and the other one slight diarrhoea. No laboratory abnormalities attributable to C-AMOX were observed in the present study.     

Clinical evaluation of effectiveness of cefmetazole in bone and joint infections in the orthopedic field

1. Cefmetazole (CMZ) was administered to a total number of 12 patients, 10 having acute or chronic osteomyelitis and 2 pyarthrosis in the orthopedic field. The efficacy rate was 91.7%. 2. Patients received an intravenous instillation of 1 to 2 g CMZ daily for an average period of 29.8 days. 3. Causative organisms were identified in 8 of the cases examined. In 7 cases S. aureus was isolated. CMZ showed an extremely strong antibacterial activity against S. aureus in a disk test in support of its excellent clinical results. 4. No abnormality was found with respect to subjective and objective symptoms and in laboratory tests. 5. The above results and migration of CMZ into the bone tissue at a high concentration suggest that CMZ is an effective and safe drug for bone and joint infection in the orthopedic field.     

Laboratory and clinical studies of cefmetazole in serious infection by Staphylococcus (author's transl)

Cefmetazole (CMZ) is an antibiotic agent belonging to the cephamycin group, which is resistant to beta-lactamase and has a broad antibacterial spectrum covering from Gram-negative to -positive organisms. Although this agent has been proved to have an antibacterial activity against Staphylococcus spp., it has not been used for treatment of the infections caused by the organism. Thus, 62 strains of S. aureus isolated clinically were compared for their sensitivity to CMZ, cefoxitin (CFX), cefuroxime (CXM), cefazolin (CEZ), and ampicillin (ABPC). In addition, 5 children suffering from septicemia due to S. aureus were treated with CMZ 158 mg/kg at a mean daily dose for a mean period of 14 days. The dose was used after dividing into 3 and 4 equal parts in 1 and 4 children, respectively. One old patient with septicemia was given 2,000 mg of CMZ twice daily for 4 days and once daily for subsequent 3 days. Another child with bacterial meningitis was treated with 50 mg/kg of CMZ 4 times daily for 63 days. The drug was given intravenous injection by one-shot or drip infusion in all cases under observation of clinical effects, bacteriological effects and side effects. The MIC of CMZ against S. aureus at inoculum sizes of 10(6) and 10(8) cells/ml was 1.56 mcg/ml in 72.6 and 56.5% of the strains, respectively. When 5 drugs were compared on the basis of the MIC to which the largest number of strains were sensitive, CEZ was most active, and CMZ was ranked in the next place and similar to CXM in activity. However, when the whole range of the MIC was considered, CMZ was more excellent than CXM, its MIC was lower than those of CEZ, CFX and ABPC in a greater number of strains. It was considered from the results that the serum level of CMZ was effective against 100 and 93.5% of strains at an inoculum size of 10(6) cells/ml and against 100 and 83.9% of strains at an inoculum size of 10(8) cells/ml until 4 and 6 hours after a one-shot intravenous injection of 50 mg/kg of Moni-trol I standard, respectively in the children. Thus, CMZ is expected to manifest a sufficient effect on septicemia caused by S. aureus in children who receive a one-shot intravenous injection of 50 mg/kg of it 4 times daily. Treatment with CMZ was clinically evaluated to be excellent in 3, good in 3 and poor in none of 6 patients with septicemia due to S. aureus, and fair in the 1 with Staphylococcal meningitis. The bacteriological result was excellent, since the causal organisms were eradicated in all cases. With regard to side effects, abnormal eosinophilia was found in 2 cases, but it was no ascribable to this drug in 1 of them. GOT showed an abnormal rise in 1 case and both GOT and GPT in 1, although they were considered not to be related to this drug in either case. It is considered from these results that CMZ is a valuable drug in treatment of septicemia due to S. aureus.     

Double-blind comparison of cefotetan and cefmetazole in complex urinary tract infections

For the purpose of carrying out an objective evaluation of the clinical efficacy and safety of cefotetan (CTT), a new cephamycin-type injectable antibiotic, in the treatment of complicated urinary tract infections, cefmetazole (CMZ) was employed as the control drug in a comparative study performed by the double-blind method. CTT was administered in a dose of 0.5 g or 1 g, while CMZ was used in a dose of 1 g; both of these drugs were administered by intravenous drip infusion twice a day for 5 days. The total number of treated cases was 393; 105 patients in the CTT 1 g group, 97 patients in the CTT 2 g group, and 96 patients in the CMZ 2 g group. The judgment of the clinical effects of these 3 therapeutic regimens was carried out in accordance with the criteria for evaluation of clinical efficacy of antimicrobial agents on UTI (2nd edition). The results are as follows. With regard to the overall efficacy of the drug treatments, the calculated efficacy rates were 54.3% in the CTT 1 g group, 63.9% in the CTT 2 g group and 52.1% in the CMZ 2 g group. The differences between these efficacy rates were not statistically significant. Regarding the efficacy of the treatments in terms of the bacteriuria, the bacterial cultures were seen to become negative in 40% of the cases in the CTT 1 g group, 54.6% of the CTT 2 g group and 42.7% of the CMZ 2 g group. Again, there were no statistically significant differences between the groups. Concerning the efficacy of the drugs against pyuria, by combining the cases found to be normalized and those seen to show improvement, the improvement rates were calculated to be 41.9% for the CTT 1 g group, 37.1% for the CTT 2 g group, and 37.5% for the CMZ 2 g group. These pyuria improvement rates show no statistically significant differences, respectively. The incidences of occurrence of side effects and laboratory test abnormalities thought to be caused by the drug therapy were as follows; 1.5% and 5.3% in the CTT 1 g group, 1.5% and 3.1% in the CTT 2 g group and 0% and 6.9% in the CMZ 2 g group. There were no significant differences between the groups. Based on the above clinical results, it can be concluded that, in the treatment of complicated urinary tract infections, we can expect CTT to provide the same therapeutic efficacy as CMZ when its dosage is the same or even half thereof. In addition, the safety of CTT is equal to that of CMZ. Therefore, CTT is concluded to be a useful drug.     

Clinical experience with T-1982 (cefbuperazone) in the pediatric field

T-1982 (cefbuperazone) was given intravenously to 21 children with the following acute bacterial infections; 13 cases of bronchopneumonia, 2 cases of urinary tract infection, 1 case of subcutaneous abscess, 1 case of cervical purulent lymphadenitis and acute tonsillitis, and 4 cases of acute bronchitis. Clinical effectiveness was obtained in 20 cases out of 21 cases and bacteriological effectiveness in 7 cases out of 8 cases. As for the side effects, 1 patient had asymptomatic eosinophilia, but no other laboratory abnormalities were observed. Above results suggest that T-1982 is a useful antibiotic for treating pediatric patients with various kinds of bacterial infections.     

Pharmacokinetics of cefmetazole during and after surgical operations

Cefmetazole (CMZ), with its relatively broad antibacterial spectrum, good stability to beta-lactamases and a high degree of safety, has established a place in the antibacterial therapy. In this study the pharmacokinetics of CMZ during and after surgical operations were investigated. CMZ in a dose of 2 g was administered intravenously to 15 cases operated upon for ailments of abdominal organs (10 cases of cholecystolithiasis and 5 cases of early or resectable gastric cancer). The serum samples were taken during and on the 2nd or the 3rd day after operation. Concentrations of CMZ in serum were measured by bioassay with Micrococcus luteus ATCC 9341 and by a high performance liquid chromatography (HPLC) method. CMZ concentrations during the operation was at higher level than on the 2nd or the 3rd day after the operation. In cholecystolithiasis, the half-life time (T 1/2) was 2.11 hours during operation and 1.42 hours after the operation. In cases of gastric cancer, T 1/2 was 1.31 hours during operation and 2.21 hours after the operation. In cholecystolithiasis, area under the curves (AUCs) were 469.39 micrograms.hr/ml during operation and 294.44 micrograms.hr/ml after the operation. In cancer cases, AUC's were 339.83 micrograms.hr/ml during and 329.75 micrograms.hr/ml after operation. Any postoperative infections and adverse reactions were not observed in these cases. Therefore, CMZ would be very effective and available for its prophylactic role.     

Experimental and clinical evaluation of T-1982 (cefbuperazone) in the field of obstetrics and gynecology

Experimental and clinical studies of T-1982 (cefbuperazone), a new cephamycin antibiotic, were performed in the field of obstetrics and gynecology, and the following results were observed. T-1982 was determined for its in vitro activity against 180 recent clinical isolates in comparison with cefmetazole (CMZ) and cefazolin (CEZ). The activity of T-1982 was superior to that of CMZ against E. coli (101 strains) and B. fragilis (19 strains), and similar to that of CMZ and CEZ against Peptococcus (34 strains). High concentrations of T-1982 exceeding the MIC values against various bacteria were maintained for a few hours in the female genital organs and postoperative retroperitoneal exudate after intravenous drip infusion of 2 g. T-1982 was administered to a total of 6 patients in daily dose of 2 approximately 3 g for 2 approximately 10 days. The clinical results were excellent or good in 5 cases. Drug eruption was observed in 1 case. These results suggest that T-1982 is highly effective for the treatment of bacterial infections in this field.